{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:15:28Z","timestamp":1780409728882,"version":"3.54.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To report the case of a patient with refractory neuromyelitis optica spectrum disorder (NMOSD), who, despite showing poor response or intolerance to multiple immunosuppressants, was successfully treated with Ofatumumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 42-year-old female was diagnosed with NMOSD in the first episode of the disease. Despite treatment with intravenous methylprednisolone, immunoglobulin, rituximab and immunoadsorption, together with oral steroids, azathioprine, mycophenolate mofetil and tacrolimus, she underwent various adverse events, such as abnormal liver function, repeated infections, fever, rashes, hemorrhagic shock, etc., and experienced five relapses over the ensuing four years. Finally, clinicians decided to initiate Ofatumumab to control the disease. The patient received 9 doses of Ofatumumab over the next 10 months at customized intervals. Her symptoms were stable and there was no recurrence or any adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ofatumumab might serve as an effective and safe alternative for NMOSD patients who are resistant to other current immunotherapies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1208017","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T09:54:11Z","timestamp":1687946051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A meaningful exploration of ofatumumab in refractory NMOSD: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Yibo","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1517\/13543780902832679","article-title":"Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders","volume":"18","author":"Castillo","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000683","article-title":"Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder","volume":"7","author":"Maillart","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1047992","article-title":"Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: a case report","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578035","article-title":"The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous ofatumumab","volume":"376","author":"Gou","year":"2023","journal-title":"J Neuroimmunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained b-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Mult Scler"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory b-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J Neurol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"104347","DOI":"10.1016\/j.neuint.2018.11.022","article-title":"Individualized b cell-targeting therapy for neuromyelitis optica spectrum disorder","volume":"130","author":"Kim","year":"2019","journal-title":"Neurochem Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102727","article-title":"Efficacy and safety of rituximab in treating patients with neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis","volume":"20","author":"Mirmosayyeb","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"Mabs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104524","article-title":"B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: a real-world case series study","volume":"70","author":"Cao","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory b cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders","volume":"7","author":"Lebrun","year":"2018","journal-title":"Neurol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1208017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T09:54:14Z","timestamp":1687946054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1208017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2023.1208017"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1208017","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]},"article-number":"1208017"}}